• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain
RSV Roundtable : Episode 3

RSV Roundtable: Nirsevimab's impact

News
Video

In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.

Welcome to the third episode of our 5-episode series; respiratory syncytial virus (RSV) Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.

This series discusses several aspects of RSV including incidence rates, vaccines, and immunizations.

In this episode, our panel highlights what type of impact nirsevimab (Beyfortus; Sanofi, AstraZeneca) has made this RSV season. In this discussion, the monoclonal antibody's availability and rollout process is also in the spotlight amid a plan to roll out some 230,000 additional doses in January 2024.

Our panel of clinicians includes:

  • Robert H. Hopkins Jr., MD: medical director, National Foundation for Infectious Diseases; professor of Internal Medicine and Pediatrics; chief, Division of General Internal Medicine, University of Arkansas for Medical Sciences
  • William Muller, MD, PhD: attending physician, Infectious Diseases; Ted Emerson Miller research scholar; professor of Pediatrics (Infectious Diseases), Northwestern University Feinberg School of Medicine; scientific director, Clinical and Community Trials, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children’s Hospital
  • Sallie Permar, MD, PhD: Nancy C. Paduano professor and chair, Department of Pediatrics, Weill Cornell Medicine; pediatrician-in-chief, New York-Presbyterian/Weill Cornell Medical Center
  • Laura Riley, MD: chair, Department of Obstetrics and Gynecology, Weill Cornell Medicine; obstetrician and gynecologist-in-chief, New York-Presbyterian/Weill Cornell Medical Center
  • Neil Silverman, MD: professor, obstetrics and gynecology, David Geffen School of Medicine, UCLA; director, Maternal-Fetal Medicine Fellowship Program

Click here for the first episode of RSV Roundtable.

Click here for the second episode of RSV Roundtable.

This series will release a new episode every Friday through January 5, 2024.

For a full list of already-published episodes, click here.

Thanks for watching RSV Roundtable.

Related Videos
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
Samir Gautam, MD, PhD | Image Credit: Yale School of Medicine
John Bradley, MD
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Related Content
© 2024 MJH Life Sciences

All rights reserved.